Pre- and post-treatment lung microbiota, metabolome and immune signatures at the site of disease in patients with active pulmonary tuberculosis
活动性肺结核患者治疗前和治疗后的肺部微生物群、代谢组和疾病部位的免疫特征
基本信息
- 批准号:10445329
- 负责人:
- 金额:$ 13.09万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-06-11 至 2024-05-31
- 项目状态:已结题
- 来源:
- 关键词:Acute-Phase ProteinsAerosolsAffectAfrica South of the SaharaAfricanAftercareAnaerobic BacteriaAntibioticsAreaBacteriaBioinformaticsBiological MarkersBronchoalveolar LavageBronchoalveolar Lavage FluidBronchoscopyCD4 Positive T LymphocytesCause of DeathCellsCessation of lifeChestChronicClinicalClinical DataClinical TrialsCommunicable DiseasesComplexComputing MethodologiesContralateralCustomDataDiagnosticDiseaseDoseEpidemiologyFGF2 geneFermentationFoundationsGrowth FactorHIVHIV SeronegativityHIV SeropositivityHIV/TBHealthHelicobacterHemophilusHuman MicrobiomeHuman bodyImmuneImmune responseImmunityImmunologic MarkersImmunologicsImmunologyImpairmentInflammationInflammatoryInterferon Type IIInterleukin-1Interleukin-17Interleukin-4Interleukin-6KnowledgeLinkLong-Term EffectsLower respiratory tract structureLungLung diseasesLung immune responseMass FragmentographyMatrix MetalloproteinasesMeasurementMeasuresMetabolicMetadataMethodsMouth DiseasesMusMycobacterium tuberculosisNew YorkOutcomePathogenesisPatient RecruitmentsPatientsPeptide HydrolasesPersonsPopulationPredispositionPrevotellaProbioticsProceduresProductionPulmonary TuberculosisRNARegimenRelapseResearchResearch TrainingRespiratory DiseaseRibosomal RNARoleSamplingScientistSerumSiteSouth AfricaSouth AfricanSpecimenStructure of parenchyma of lungT-Cell DepletionT-LymphocyteT-Lymphocyte EpitopesTNF geneTechnologyTestingTherapeuticTherapeutic InterventionTimeTissuesTrainingTransforming Growth Factor betaTreatment FailureTuberculosisUnited StatesUniversitiesVaccinesVascular Endothelial Growth FactorsVeillonellaVisitVolatile Fatty Acidsantiretroviral therapybacterial communitycytokinegut microbiotahost microbiotaimprovedimproved outcomelung microbiotamacrophagemetabolomemicrobialmicrobial communitymicrobial hostmicrobiomemicrobiotamortalitynano-stringnon-tuberculosis mycobacterianoveloral anaerobesprebioticsprogramspublic health emergencyrecruitresiliencerespiratory healthrespiratory microbiotascale upseropositivetherapeutic targettissue repairtreatment responsetreatment sitetuberculosis treatment
项目摘要
SUMMARY
The human microbiome is important for infectious disease pathogenesis. However, our understanding of the
microbiome’s role in tuberculosis (TB), which is arguably the most important lung disease in the world, is
extremely limited. In sub-Saharan Africa, TB is exacerbated by HIV which, even with antiretroviral therapy, results
in reduced pulmonary immunity. The site-of-disease in active TB (bronchoalveolar space) is a unique
environmental and immunological niche but its microbiota is surprisingly understudied. We do not know how
taxa, including those important for lung heath (oral anaerobic fermenters), correlate with bacterial fermentation
end-products like short chain fatty acids (SCFAs), which may influence immunological control of TB and tissue
repair. Furthermore, the TB regimen is comprised of thousands of doses of antibiotics yet its long-term effect on
the lung microbiota is hitherto uncharacterized. We hence lack key foundational knowledge that precludes
research on the lung microbiota as a potential diagnostic or therapeutic target to improve TB outcomes.
We will test our central hypothesis that site-of-disease oral anaerobic fermenters are associated with elevated
pulmonary SCFAs and impaired inflammation and tissue repair biomarkers in TB cases (n=50) and, at treatment
end, these taxa and biomarkers remain perturbed but improve a year later. We will recruit an equal number of
HIV-positive patients at our high TB-HIV burden site in Cape Town. We will test our central hypothesis using
three aims. Aim 1 will, using a modified bronchoalveolar lavage (BAL) procedure, compare the site-of-disease
microbiota to that in contralateral non-diseased lung tissue before treatment. Aim 2 will characterize, at each
lung site before treatment, the association between specific taxa, SCFAs, inflammation and tissue repair
biomarkers, and investigate whether SCFA addition to ex vivo stimulated BAL cells impairs immune marker
release in a dose-dependent manner. Aim 3 will re-sample patients by bronchoscopy at treatment end and a
year later, and repeat measurements of the microbiota, SCFAs, and host biomarkers at each lung site.
If the site-of-disease is associated with a perturbed microbiota, linked via SCFAs, to impaired pulmonary
immunity and tissue repair, including after treatment, it will justify study of the microbiota and long-term TB clinical
outcomes (e.g., progression, treatment failure, relapse), which requires large and expensive trials. It will enable
research on tests or therapeutic interventions (antibiotics, drugs, prebiotics, vaccines) that target the microbiota.
Key to achieving our aims are the transfer of the modified bronchoscopy and BAL microbiota sampling
procedure (required to minimize cross contamination in low microbial abundance lower airway specimens) and
leading-edge computational expertise (required to co-analyze sequence data in conjunction with biomarker and
clinical data) from New York University to Stellenbosch University (SU). South African clinicians and scientists
will train in each area by through research and training visits with the long-term aim of establishing a research
program on the lung microbiota and respiratory health at SU.
总结
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Grant de Vos Theron其他文献
Grant de Vos Theron的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Grant de Vos Theron', 18)}}的其他基金
Pre- and post-treatment lung microbiota, metabolome and immune signatures at the site of disease in patients with active pulmonary tuberculosis
活动性肺结核患者治疗前和治疗后的肺部微生物群、代谢组和疾病部位的免疫特征
- 批准号:
10625356 - 财政年份:2019
- 资助金额:
$ 13.09万 - 项目类别:
相似海外基金
AEROSOLS - AIR QUALITY AND HEALTH IMPACT OF PRIMARY SEMI-VOLATILE AND SECONDARY PARTICLES AND THEIR ABATEMENT
气溶胶 - 一次半挥发性颗粒和二次颗粒对空气质量和健康的影响及其消除
- 批准号:
10092043 - 财政年份:2024
- 资助金额:
$ 13.09万 - 项目类别:
EU-Funded
Molecular-level Understanding Of Atmospheric Aerosols (MUOAA 2024); Corsica, France; April 1-5, 2024
对大气气溶胶的分子水平理解(MUOAA 2024);
- 批准号:
2332007 - 财政年份:2024
- 资助金额:
$ 13.09万 - 项目类别:
Standard Grant
TWISTA (The Wide-ranging Impacts of STratospheric smoke Aerosols)
TWISTA(平流层烟雾气溶胶的广泛影响)
- 批准号:
NE/Y000021/1 - 财政年份:2024
- 资助金额:
$ 13.09万 - 项目类别:
Research Grant
TWISTA (The Wide-ranging Impacts of STratospheric smoke Aerosols)
TWISTA(平流层烟雾气溶胶的广泛影响)
- 批准号:
NE/Y000358/1 - 财政年份:2024
- 资助金额:
$ 13.09万 - 项目类别:
Research Grant
Southern Ocean aerosols: sources, sinks and impact on cloud properties
南大洋气溶胶:来源、汇以及对云特性的影响
- 批准号:
DP240100389 - 财政年份:2024
- 资助金额:
$ 13.09万 - 项目类别:
Discovery Projects
INvestigating Home water and Aerosols' Links to opportunistic pathogen Exposure (INHALE): do consumer decisions impact pathogen exposure and virulence?
调查家庭用水和气溶胶与机会性病原体暴露(吸入)的联系:消费者的决定是否会影响病原体暴露和毒力?
- 批准号:
2326096 - 财政年份:2023
- 资助金额:
$ 13.09万 - 项目类别:
Standard Grant
An AI-driven clinical washbasin unit that automatically disinfects pathogens, reduces aerosols and decreases healthcare-acquired infections by 70%
%20人工智能驱动%20临床%20洗脸盆%20单位%20%20自动%20消毒%20病原体,%20减少%20气溶胶%20和%20减少%20医疗保健获得性%20感染%20by%2070%
- 批准号:
83001507 - 财政年份:2023
- 资助金额:
$ 13.09万 - 项目类别:
Innovation Loans
Cloudbusting with JWST: characterising aerosols, aurorae and chemistry in substellar atmospheresto the water cloud regime
使用 JWST 进行云消除:描述水云状态下恒星大气中的气溶胶、极光和化学成分
- 批准号:
ST/X001091/1 - 财政年份:2023
- 资助金额:
$ 13.09万 - 项目类别:
Research Grant
Bioactivated Aerosols for Combustion Product Capture
用于燃烧产物捕获的生物活性气溶胶
- 批准号:
10080253 - 财政年份:2023
- 资助金额:
$ 13.09万 - 项目类别:
Small Business Research Initiative














{{item.name}}会员




